Russia's Channel One refuses to broadcast Samoilova's performance via satelliteSociety & Culture March 23, 21:52
Experts forecast Bank of Russia will keep key rate at 10%Business & Economy March 23, 21:13
Putin's aide explains why Russia has no fear of supplying S-400 systems to TurkeyRussian Politics & Diplomacy March 23, 20:42
British police identify Westminster attacker as Khalid MasoodWorld March 23, 20:03
Russia develops ‘grenade launcher-propelled’ reconnaissance droneMilitary & Defense March 23, 19:58
Ukraine forbids Russian Eurovision contestant to perform via satelliteWorld March 23, 19:35
Jehovah’s Witnesses in Russia suspended over extremismSociety & Culture March 23, 19:00
Kiev confirms Russian politician’s killer dies in hospitalWorld March 23, 18:31
Russia to develop Tor air defense missile system’s Arctic versionMilitary & Defense March 23, 18:30
ANNAPOLIS, Maryland, Sept. 15, 2015 /PRNewswire/ - The Plasma Protein Therapeutics Association (PPTA) and its member companies are sponsoring the third annual International Plasma Awareness Week, October 11-17.
Logo - http://photos.prnewswire.com/prnh/20150914/266390LOGO
Photo - http://photos.prnewswire.com/prnh/20140910/145293-INFO
International Plasma Awareness Week (IPAW) is designed to:
PPTA member companies have planned a variety of activities at plasma collection facilities in the U.S. and Europe. In addition, patient organizations representing individuals who rely on plasma protein therapies that treat rare diseases have pledged their support.
"Patients throughout the world rely on plasma protein therapies which are developed through the generosity and commitment of plasma donors. PPTA is proud of the contributions industry makes to saving and improving lives," said Joshua Penrod, PPTA Vice President, Source and International Affairs.
Plasma protein therapies, which include plasma-derived therapies and recombinant analogs, are used to treat chronic, life-threatening diseases including bleeding disorders, primary immune deficiencies, alpha-1 antitrypsin deficiency and certain rare neurological disorders. In addition, these therapies are used in emergency and surgical medicine.
There are more than 500 plasma collection facilities in Canada, Austria, Hungary, the Czech Republic, Germany, and the U.S. In addition to meeting regulatory requirements, the majority of these centers have achieved International Quality Plasma Program certification, PPTA's voluntary standards program that provides global leadership for the industry's goal of continuous improvement with a focus on safety and quality from the donor to the patient.
The Plasma Protein Therapeutics Association (PPTA), a global industry trade association, represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. Millions of people use these therapies worldwide to treat a variety of diseases and serious medical conditions. PPTA also administers standards and programs that help ensure the quality and safety of plasma protein therapies, donors and patients.
Rachel Liebe, Project Coordinator, Communications, +1.443.433.1118